PA3-17

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NamePA3-17
Drug Alias NamePA3-17
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT-cell antigen CD7 inhibitorsImmunologic cytotoxicityT lymphocyte replacements
TargetsT-cell antigen CD7
Therapy Area/IndicationsT lymphoblastic lymphomaHematologic NeoplasmsLymphoma, T-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co LtdPersongen Anke Cell Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsT lymphoblastic lymphomaHematologic NeoplasmsLymphoma, T-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A